Treatment of adjuvant arthritis using microencapsulated antisense NF-B oligonucleotides

Journal of Microencapsulation

Volumn 26, Issue 3, 2009, Pages 223-234

  Akhavein, Nima ^a   Oettinger, Carl W ^b   Gayakwad, Sanjay G ^a   Addo, Richard T ^a   Bejugam, Naveen K ^a   Bauer, John D ^a   Do, Duc ^a   Pollock, Stanley H ^a   D'Souza, Martin J ^a  

^a MERCER UNIVERSITY   (United States)

^b Dialysis Clinic Inc   (United States)

Author keywords

Adjuvant arthritis; Albumin; Microspheres; NF B

Indexed keywords

ALBUMIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN ANTISENSE OLIGONUCLEOTIDE; MICROSPHERE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; IN VITRO STUDY; INFLAMMATION; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN; PAW EDEMA; RAT;

ALBUMINS; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL LINE; DOWN-REGULATION; MALE; MICROSPHERES; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70749116093     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/02652040802268691     Document Type: Article

References (44)

1. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, et al. Is NF--B a useful therapeutic target in rheumatoid arthritis?. Ann Rheum Dis. 2002;61(Suppl II):ii13-ii18.
2. Tsao PW, Tatsuo S, Totsuka R, Murata T, Takagi T, Ohmachi Y, et al. The effect of dexamethasone on the expression of activated NF--B in adjuvant arthritis. Clin Immunol Immunopathol. 1997;83:173-178.
3. Barnes PJ, Karin M. Nuclear factor kappa B-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336:1066-1077.
4. Ghosh S, May MJ, Kopp EB. NF-kappa B and rel proteins: Evolutionarily conserved mediators of immune responses. Annl Rev Immunol. 1998;16:225-260.
5. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B: An emerging theme in anti-inflammatory therapies. Molec Intervent. 2002;2:22-32.
6. Li Q, Verna IM. NF-kappa B regulation in the immune system. Nature. 2002;2:725-734.
7. Tak PP, Firestein GS. NF-kappa B: A key role in inflammatory diseases. J Clin Invest. 2002;107:7-11.
8. D'Souza MJ, Jin Z, Oettinger CW. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF--B. J Interferon Cytokine Res. 2005;25:311-320.
9. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosupression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995; 270:286-290.
10. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
11. Ardite E, Panes J, Miranda M, Salas A, Eizalde JI, Sans M, et al. Effects of steroid treatment on activation of nuclear factor kappa B in patients with inflammatory bowel disease. Br J Pharmacol. 1998; 124:431-433.
12. Khaled AR, Soares LS, Butfiloski EJ, Stekman I, Sobel ES, Schiffenbauer J. Inhibition of the p50 subunit of NF-kappa B by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-kappa B expression and immunoglobulin synthesis in murine B cells. Clin Immunol Immunopathol. 1997;83:254-263.
13. Schlaak JF, Barreiros AP, Pettersson S, Schirmacher P, Meyer KH, Neurath MF. Antisense phosporothioate oligonucleotide to the p65 subunit of NF-kappa B abrogates fulminant septic shock induced by S. typhimurium in mice. Scand J Immunol. 2002;54:396-403.
14. Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 1992;2:139-144.
15. Lewis KJ, Irwin WJ, Akhtar S. Biodegradable poly (L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. J Contr Rel. 1995;37:173-183.
16. Akhtar S, Lewis KJ. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int J Pharm. 1997;151:57-67.
17. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of phosporothioates in mice. Proc Natl Acad Sci USA. 1999;88:7595-7599.
18. De Rosa G, Maiuri MC, Ungaro F, De Stefano D, Quaglia F, La Rotonda I, et al. Enhanced intracellular uptake and inhibition of NF-kappa B activation by decoy oligonucleotide released from PLGA microspheres. J Gene Med. 2005;7:77-78.
19. Khan A, Benboubetra M, Sayyed PZ, Wooi K, Fox S, Beck G, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and Ribozymes: In vitro and in vivo studies. J Drug Target. 2004;12:393-404.
20. Oettinger CW, D'Souza MJ, Akhavein N, Peer GT, Taylor FB. Proinflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kB. J Microencapsulation. 2007; 24:337-348.
21. Von Hoegen I, Waller C. Safety of human albumin based on spontaneously reported adverse events. Crit Care Med. 2001;29:994-996.
22. Vincent J-L, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: A meta-analysis of randomized, controlled trials. Crit Care Med. 2004;32:2029-2038.
23. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers- liposomes and microspheres-on the phagocytosis of microspheres. J Contr Rel. 2002;79:29-40.
24. Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: Effects of size and surface properties of the microspheres. Coll Surf B Biointerfaces. 2003;27:33-39.
25. Oettinger CW, D'Souza MJ, Milton GV. Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in gram-negative peritonitis. J Interferon Cytokine Res. 1999; 19:33-40.
26. Oettinger CW, D'Souza MJ. Microencapsulation of tumor necrosis factor oligomers: A new approach to pro-inflammatory cytokine inhibition. J Interferon Cytokine Res. 2003;23:533-543.
27. D'Souza MJ, Oettinger CW, Milton GV, Tracey KJ. Prevention of lethality and suppression of pro-inflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J Interferon Cytokine Res. 1999;19:1125-1133.
28. D'Souza MJ, Oettinger CW, Shah A, Tipping PG, Huang XR. Macrophage depletion by albumin microencapsulated clodronate: Attenuation of cytokine release in macrophage dependent glomerulonephritis. Drug Dev Ind Pharm. 1999;25:591-596.
29. Zhaowei J, D'Souza MJ, Oettinger CW. Reversal of LPS induced endothelial cell TNF synthesis and increased permeability with microencapsulated antisense oligomers to NF-B. J Microencapsulation. 2007;24:596-607.
30. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine. 1993;5:298-304.
31. Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Haines K, et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. 2000;43:1266-1277.
32. Cooper WG, Fava RA, Gates CA, Cremer CA, Townes AS. Acceleration of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol. 1992;89:244-250.
33. Feige U, Hu Y, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti interleukin-1 and anti-tumor necrosis factor-synergistically inhibit adjuvant arthritis in lewis rats. Cell Molec Life Sci. 2000; 57:1457-1470.
34. Asahara H, Asanuma M, Ogawa M, Nishsibayashi S, Inoue H. High DNA binding activity of transcription factor NF-B in synovial membranes of patients with rheumatoid arthritis. Biochem Molec Biol Int. 1995;37:827-832.
35. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, et al. Activation of the transcription factor nuclear factor-B in human inflamed synovial tissue. Arthritis Rheum. 1996;39:583-591.
36. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-B regulation in rheumatoid arthritis and murine collagen arthritis. Autoimmunity. 1998;28:197-208.
37. Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamachi H, Honda S, et al. Importance of NF--B in rheumatoid synovial tissues: In situ NF--B expression and in vitro study using cultured synovial cells. Ann Rheum Dis. 2001; 60:678-684.
38. Benito MJ, Murphy E, Murphy EP, Van Den Berg WB, FitzGerald O, Bresnihan B. Increased synovial tissue NF--B expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum. 2004;50:1781-1787.
39. Carlsen H, Moskaug JO. In vivo imaging of NF-B activity. J Immunol. 2002;68:1141-1146.
40. Pahl HL. Activators and target genes of Rel/NF-B transcription factors. Oncogene. 1999;18:6853-6866.
41. D'Acquisto F, Ialenti A, Ianaro A, Di Vaio R, Carnuccio R. Local administration of transcription factor decoy oligonucleotides to nuclear factor-B prevents carrageenin-induced inflammation in rat hind paw. Gene Therapy. 2000;7:1731-1737.
42. Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, et al. Transcription factor decoy for NF-B inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology. 2000;39:749-757.
43. Keystone EC. Tumor necrosis factor--blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin N Am. 2001;27:427-443.
44. Pearce GP, Chikanza IC. Targeting tumour necrosis factor in the treatment of rheumatoid arthritis. BioDrugs. 2001;15:39-149.